Trial · NCT02889796
Outcomes80
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 80
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 12 | Week 12 | The Full Analysis Set included participants who were randomized and received at least 1 dose of study drug. | percentage of participants | NUMBER |
| SECONDARY | Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 12 | Baseline; Week 12 | Participants in the Full Analysis Set with available data were analyzed. | score on a scale | MEAN |
| SECONDARY | Percentage of Participants Who Achieved Disease Activity Score for 28 Joint Count Using C-Reactive Protein [DAS28 (CRP)] < 2.6 at Week 12 | Week 12 | Participants in the Full Analysis Set were analyzed. | percentage of participants | NUMBER |
| SECONDARY | Change From Baseline in Modified Total Sharp Score (mTSS) at Week 24 | Baseline; Week 24 | Participants in the Full Analysis Set with available data were analyzed. | score on a scale | MEAN |
| SECONDARY | Percentage of Participants Who Achieved DAS28 (CRP) ≤ 3.2 at Week 12 | Week 12 | Participants in the Full Analysis Set were analyzed. | percentage of participants | NUMBER |
| SECONDARY | Change From Baseline in 36-Item Short Form Survey (SF-36) Physical Component Summary (PCS) Score at Week 12 | Baseline; Week 12 | Participants in the Full Analysis Set with available data were analyzed. | score on a scale | MEAN |
| SECONDARY | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Week 12 | Baseline; Week 12 | Participants in the Full Analysis Set with available data were analyzed. | score on a scale | MEAN |
| SECONDARY | Percentage of Participants Who Achieved ACR 50% Improvement (ACR50) at Weeks 2, 4, 12, and 24 | Weeks 2, 4, 12, and 24 | Participants in the Full Analysis Set were analyzed. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Who Achieved ACR50 at Weeks 36, and 52 | Weeks 36, and 52 | Participants in the Full Analysis Set were analyzed. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Who Achieved ACR 70% Improvement (ACR70) at Weeks 2, 4, 12, and 24 | Weeks 2, 4, 12, and 24 | Participants in the Full Analysis Set were analyzed. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Who Achieved ACR70 at Weeks 36, and 52 | Weeks 36, and 52 | Participants in the Full Analysis Set were analyzed. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Who Achieved ACR20 Response at Weeks 2, 4, and 24 | Weeks 2, 4, and 24 | Participants in the Full Analysis Set were analyzed. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Who Achieved ACR20 Response at Weeks 36, and 52 | Weeks 36, and 52 | Participants in the Full Analysis Set were analyzed. | percentage of participants | NUMBER |
| SECONDARY | Change From Baseline in Individual ACR Component: HAQ-DI at Weeks 2, 4, and 24 | Baseline; Weeks 2, 4, and 24 | Participants in the Full Analysis Set with available data were analyzed. | score on a scale | MEAN |
| SECONDARY | Change From Baseline in Individual ACR Component: HAQ-DI at Weeks 36, and 52 | Baseline; Weeks 36, and 52 | Participants in the Full Analysis Set with available data were analyzed. | score on a scale | MEAN |
| SECONDARY | Change From Baseline in Individual ACR Component: Tender Joint Count Based on 68 Joints (TJC68) at Weeks 2, 4, 12, and 24 | Baseline; Weeks 2, 4, 12, and 24 | Participants in the Full Analysis Set with available data were analyzed. | tender joint count | MEAN |
| SECONDARY | Change From Baseline in Individual ACR Component: TJC68 at Weeks 36, and 52 | Baseline; Weeks 36, and 52 | Participants in the Full Analysis Set with available data were analyzed. | tender joint count | MEAN |
| SECONDARY | Change From Baseline in Individual ACR Component: Swollen Joint Count Based on 66 Joints (SJC66) at Weeks 2, 4, 12, and 24 | Baseline; Weeks 2, 4, 12, and 24 | Participants in the Full Analysis Set with available data were analyzed. | swollen joint count | MEAN |
| SECONDARY | Change From Baseline in Individual ACR Component: SJC66 at Weeks 36, and 52 | Baseline; Weeks 36, and 52 | Participants in the Full Analysis Set with available data were analyzed. | swollen joint count | MEAN |
| SECONDARY | Change From Baseline in Individual ACR Component: Subject's Global Assessment of Disease Activity (SGA) at Weeks 2, 4, 12, and 24 | Baseline; Weeks 2, 4, 12, and 24 | Participants in the Full Analysis Set with available data were analyzed. | score on a scale | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02889796/outcomes